Leptin and leptin receptor polymorphisms are associated with increased risk and poor prognosis of breast carcinoma by Snoussi, Kaouther et al.
BioMed  Central
Page 1 of 10
(page number not for citation purposes)
BMC Cancer
Open Access Research article
Leptin and leptin receptor polymorphisms are associated with 
increased risk and poor prognosis of breast carcinoma
Kaouther Snoussi1, A Donny Strosberg2, Noureddine Bouaouina1,3, 
Slim Ben Ahmed4, A Noureddine Helal5 and Lotfi Chouchane*1
Address: 1Laboratoire d'Immuno-Oncologie Moléculaire, Faculté de Médecine de Monastir, Université de Monastir, Tunisia, 2Department of 
Infectology, Scripps-Florida, USA, 3Department of Cancérologie Radiothérapie CHU Farhat Hached, Sousse, Tunisia, 4Department of Service de 
Carcinologie Médicale, CHU Farhat Hached, Sousse, Tunisia and 5Unité Génome, Diagnostic Immunitaire et Valorisation, Institut Supérieur de 
Biotechnologie de Monastir, Université de Monastir, Tunisia
Email: Kaouther Snoussi - naftikaouther@yahoo.fr; A Donny Strosberg - strosber@scripps.edu; 
Noureddine Bouaouina - noueddine.bouaouina@rns.tn; Slim Ben Ahmed - slim.benahmed@rns.tn; A 
Noureddine Helal - Ahmed.Helal@fphm.rnu.tn; Lotfi Chouchane* - lotfi.chouchane@planet.tn
* Corresponding author    
Abstract
Background: Leptin (LEP) has been consistently associated with angiogenesis and tumor growth.
Leptin exerts its physiological action through its specific receptor (LEPR). We have investigated
whether genetic variations in LEP and LEPR have implications for susceptibility to and prognosis
in breast carcinoma.
Methods:  We used the polymerase chain reaction and restriction enzyme digestion to
characterize the variation of the LEP and LEPR genes in 308 unrelated Tunisian patients with
breast carcinoma and 222 healthy control subjects. Associations of the clinicopathologic
parameters and these genetic markers with the rates of the breast carcinoma-specific overall
survival (OVS) and the disease free survival (DFS) were assessed using univariate and multivariate
analyses.
Results: A significantly increased risk of breast carcinoma was associated with heterozygous LEP
(-2548) GA (OR = 1.45; P = 0.04) and homozygous LEP (-2548) AA (OR = 3.17; P = 0.001)
variants. A highly significant association was found between the heterozygous LEPR 223QR
genotype (OR = 1.68; P = 0.007) or homozygous LEPR 223RR genotype (OR = 2.26; P = 0.001)
and breast carcinoma.
Moreover, the presence of the LEP (-2548) A allele showed a significant association with
decreased disease-free survival in breast carcinoma patients, and the presence of the LEPR 223R
allele showed a significant association with decreased overall survival.
Conclusion: Our results indicated that the polymorphisms in LEP and LEPR genes are associated
with increased breast cancer risk as well as disease progress, supporting our hypothesis for leptin
involvement in cancer pathogenesis.
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Background
Breast cancer is the most frequently diagnosed cancer
among women, with a lifetime incidence of about 10–
13% [1,2] but its etiology is still not fully understood.
Besides, age at menarche and menopause, diet, reproduc-
tive history, estrogen administration and genetic factors
have been suggested as risk factor for breast cancer [3-7].
Germline mutations in dominant, highly penetrant sus-
ceptibility genes, such as BRCA1 and BRCA2, have been
identified to be responsible for less than 10% of breast
carcinoma. In addition, low-penetrance genes, that also
increase susceptibility to breast cancer, have been sug-
gested. For instance, candidate low-penetrance breast can-
cer susceptibility genes include those involved in the
complex mechanisms of carcinogenesis [8].
Higher body weight appears to play a role in the develop-
ment of breast/mammary tumors. Obesity has been iden-
tified as a risk factor for breast cancer in postmenopausal
women [9-11], and higher body weight is associated with
increased incidence of both spontaneous and chemically
induced mammary tumors in rodents [12-15].
Leptin, a 16 kDa polypeptide hormone produced pre-
dominantly by white adipose tissue [16], plays an impor-
tant role in body weight homeostasis through effects on
food intake and energy expenditure [17,18]. In addition
to the regulation of body weight, leptin also influences
hematopoiesis, reproduction, angiogenesis, and immune
processes [19-22]. The leptin gene, the human homo-
logue of the rat obese gene (OB), has been cloned and
sequenced by Zhang et al. [16]. It is located on chromo-
some 7q31.3 [23,24] and expresses a 4.5 kb mRNA in adi-
pose tissue [16,25].
Leptin exerts its physiological action through the leptin
receptor (LEPR), a member of the class 1 cytokine receptor
family. LEPR was initially identified in the brain, which
explains the negative feedback mechanism of controlling
food intake and body weight [26]. However, further stud-
ies have demonstrated that LEPR is also expressed in many
other tissues and cells, including placenta, pancreas,
hematopoietic cells, liver, lung and gastric mucosal cells
[27-32].
The human LEPR gene is on chromosome 1. Six isoforms
derived from LEPR  transcription have been identified,
and a long isoform, LEPR-b, is reported to be responsible
for signal transduction [33].
In animal and human cell lines, leptin and leptin recep-
tors have also been clearly associated with enhanced in
vitro tumor proliferation and/or to in vitro and in vivo pro-
motion of angiogenesis. These effects have been docu-
mented in embryonic cells [34], adipocytes [35], glia [36],
endothelial cells [37], hematopoietic cells [38], and in
benign and malignant epithelial breast cells [39-42], kid-
ney, colon [43,44], liver [45], and pancreas [46].
In breast cancer tissue, it was shown that leptin and leptin
receptor are both expressed and that they act to favour
cancer proliferation and metastasis [47,48]. Controversial
results have been reported regarding the detection of
serum leptin levels in breast cancer patients [49,50]. How-
ever, the most recent reports indicate that higher leptin
serum levels are associated with advanced stage breast
cancer [51,52].
In humans, several polymorphisms have been identified
in the LEP and LEPR genes: a G to A substitution at nt -
2548 upstream of the ATG start site [53] in the LEP gene
5' promoter region, and an A to G substitution at nt 668
from the start codon 223 in exon 6 (Q223R) of the LEPR
gene coding for the extracellular region common to all
isoforms of LEPR [54].
The G to A substitution at -2548 of the LEP gene was asso-
ciated with leptin production [55,56]. The glutamine to
arginine substitution occurs on the LEPR gene within the
first of two putative leptin-binding regions and may be
associated with impaired signalling capacity of the leptin
receptor [57].
Enhanced gene expression and increased circulating lep-
tin levels have been reported in subjects carrying the LEPR
223R or LEP (-2548) A alleles [55-57]. The LEP (-2548) A
allele has also been associated with a two-fold increase of
leptin secretion adipocytes when compared to secretion
by adipocytes bearing only the LEP (-2548) G allele [56].
We hypothesize that these leptin and leptin receptor pol-
ymorphisms associated with higher leptin serum levels
and overexpression of leptin in adipocytes, favour breast
cancer development and aggressiveness. In the present
study, we analysed LEP (-2548) G/A and LEPR Q223R
genotypes in a series of breast cancer cases and normal
controls.
Methods
Patients and controls
The gene and allele frequencies of the LEP and LEPR genes
were determined in a group of 222 control subjects and
308 patients with breast carcinoma. Controls and patients
were selected from the same population living in the mid-
dle coast of Tunisia. Both the control and patients groups
include unrelated subjects.
Data on patient, tumour and treatment characteristics at
the study entry for each subject were collected from the
department of Radiation Oncology and Medical Oncol-BMC Cancer 2006, 6:38 http://www.biomedcentral.com/1471-2407/6/38
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ogy of Sousse Hospital (Sousse, Tunisia) between 1996
and 2003. They were selected consecutively whenever
practically feasible.
All patients included in this study had primary breast car-
cinoma, with unilateral breast tumours and with no fam-
ily history for the disease. The diagnosis of cancer was
confirmed by histopathology analyses. The patients (n =
308) had a mean age of 50 ± 24 years. The median of fol-
low-up was 36 months (range, 1–120 months). At time of
analysis, 66 patients experienced recurrence (local or dis-
tant). Among them, 35 died from breast carcinoma (54.5
%). Table 1 shows the treatment description of all
patients. A detailed description of the clinicopathologic
characteristic of this cohort has been reported elsewhere
[58] and data on tumor size at diagnosis, nodal status and
histologic grade are briefly included in Table 3.
Healthy women (n = 222) having a mean age of 48 ± 14
years, were blood donors with no evidence of any per-
sonal or family history of cancer (or other serious illness).
Samples from healthy controls were collected consecu-
tively between 1996 and 2003. Both cases and controls
were informed and gave written consent to participate in
the study and to allow their biological samples to be
genetically analyzed. Approval for the study was given by
the National Ethical Committee.
Patients treated by chemotherapy as a primary treatment
Among the 308 patients, 121 had chemotherapy as an
anticancer primary treatment. The chemotherapy induc-
tion was based in all cases on the combination of cyclo-
phosphamide (100%), 5-fluorouracil (100%) with
adriamycin (34%) or epirubicin (52%) or methotrexate
(14%). For neoadjuvant treatment, patients received four
or six chemotherapy cycles before surgery. The clinical
response to induction chemotherapy for all cases was
defined according to the following criteria: complete
response when regression of the tumour was total, partial
response when reduction of tumour size was greater then
50% and poor response when the reduction of tumour
size was less then 50% (tumour size was measured by the
bidimensional product of the horizontal and vertical
dimensions).
Genomic DNA extraction
Genomic DNA was extracted from peripheral blood leu-
kocytes by a salting procedure [59]. Briefly, 10 ml of
blood was mixed with triton lysis buffer (0.32M sucrose,
1% Triton X-100, 5 mM MgCl2, H2O, 10 mM Tris-HCl, PH
7.5). Leukocytes were spun down and washed with H2O.
The pellet was incubated with proteinase K at 56°C and
subsequently salted out at 4°C using a substrate NaCl
solution. Precipated proteins were removed by centrifuga-
tion. The DNA in supernatant fluid was precipated with
ethanol. The DNA pellet was dissolved in 400 µl H2O.
Polymorphism analysis of the -2548 G/A LEP gene
The -2548 G/A polymorphism of the LEP gene was ana-
lysed by restriction fragment length polymorphism-
polymerase chain reaction (RFLP-PCR). This method was
carried out by PCR amplification using forward primer 5'-
TTTCTGTAATTTTCCCGTGAG-3' and reverse primer 5'-
AAAGCAAAGACAGGCATAAAAA-3' in a 25 µl reaction
mixture containing genomic DNA samples (100 ng), 200
µmol/L dNTPs, 1.5 mM MgCl2, 1 X Taq polymerase
buffer, 50 pmol of each primer, and 0.5 unit of Taq DNA
polymerase (Amersham, Paris, France). Reaction condi-
tions used with the thermal cycler (Biometra, GÖttingem,
Germany) were as follows: an initial incubation at 94°C
for 5 minutes followed by 30 cycles of incubation at 94°C
for 45 seconds, 52°C for 45 seconds and 72°C for 45 sec-
onds with a final extension at 72°C for 7 minutes. The
PCR product (242 bp) was verified by DNA sequencing.
The amplified products were digested with the addition of
2 U CfoI for 3 hours at 37°C. The digested samples were
separated by electrophoresis through a 2% agarose gels
and stained with ethidium bromide. The polymorphism
was defined by presence (G) or absence (A) of the CfoI
restriction site. To assess reliability of genotyping we per-
formed double sampling RFLP-PCR in more than 10% of
the samples and found no differences.
Polymorphism analysis of the LEPR gene
Based on the method described by Gotoda et al. [54], a
PCR followed by digestion with endonuclease MspI was
used to detect the A  to G  transition polymorphism at
codon 223 of LEPR gene. Two sequence specific oligonu-
Table 1: Treatment description of the 308 patients with Breast Carcinoma
Surgery No surgery
Radiotherapy 33 14
Chemotherapy 28 14
Radiotherapy + Chemotherapy 137 18
Radiotherapy + endocrine therapy 14 0
Chemotherapy + endocrine therapy 7 4
Radiotherapy + Chemotherapy + endocrine therapy 39 0BMC Cancer 2006, 6:38 http://www.biomedcentral.com/1471-2407/6/38
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cleotides primers were used for the polymerase chain reac-
tion (PCR): the 3' primer 5'-
AAACTCAACGACACTCTCCTT- 3' and 5' primer 5'-
TGAACTGACATTAGAGGTGAC- 3'. PCR was performed
by using 100 ng genomic DNA as template, 0.01 mM
dNTPs, 1.5 mM MgCl2, 1 X Taq polymerase buffer,
0.75µM of each primer and 0.5 U of Taq DNA polymerase
in a total reaction of 25 µl. Reaction conditions used with
the thermal cycler were as follows: 94°C for 5 min fol-
lowed by 35 cycles at 94°C for 30 seconds, 52°C for 45
seconds and 72°C for 45 seconds. A final extension step
was carried out at 72°C for 5 min.
The PCR products (80 bp) were electrophoresed on a 3%
agarose gel containing ethidium bromide to monitor
amplification and possible contamination. The PCR prod-
uct (80 bp) was verified by DNA sequencing. The 80 bp
PCR products were digested with MspI and analysed on
4% (3:1 Nusieve: Normal) agarose gels because of the
small DNA products size. The presence of MspI site was
indicated by the cleavage of the amplified product into
two fragments of 57 and 23 bp. The two allelic forms of
LEPR, corresponding to the absence or the presence of the
MspI site, are referred to as 223Q and 223R, respectively.
Statistical analyses
The allele frequencies of LEP and LEPR were tested for the
Hardy-Weinberg equilibrium for both patient and control
groups using the chi-square test. The same test was used to
evaluate for significant association between disease
(breast carcinoma versus controls) and LEP or LEPR geno-
types or alleles.
Disease-free survival (DFS) was defined as the time from
the date of diagnosis to the first local or distant recurrence
or to last contact. Breast carcinoma-specific overall sur-
vival (OVS) was defined as the time from the date of diag-
nosis to death if the patient died from breast carcinoma or
to last contact. Six-year survival rates were estimated, and
survival curves were plotted according to Kaplan and
Meier [60]. The differences between groups were calcu-
lated by the log-rank test [61].
Clinicopathological parameters were dichotomised as fol-
lows: nodal status (≥ 1 versus no positive lymph node),
SBR (Scarff, Bloom and Richardson) tumour grade (1–2
versus 3), clinical tumour size (T1-T2 versus T3-T4).
Statistics were performed using SEM-STATISTIQUES soft-
ware (centre Jean Perrin, Clermont-Ferrand, France).
Results
Polymorphisms in the LEP and LEPR genes as risk factor 
for breast carcinoma
The genotype distribution and allele frequencies for the
LEP (-2548) G/A and LEPR Q223R polymorphisms in all
patients with breast carcinoma and in the control group
are presented in Table 2. The allele frequencies of LEP and
LEPR genes were in Hardy-Weinberg equilibrium in both
patient and control groups (P = 0.55, P = 0.7; P = 0.17, P
= 0.376 respectively).
A significantly higher risk for breast cancer was observed
for carriers of LEP (-2548) AA genotype (Odds Ratio (OR)
= 3.17; P = 0.001) and carriers of LEP (-2548) GA geno-
Breast carcinoma specific overall survival (A1) and specific disease-free survival (A2) of 308 breast carcinoma patients accord- ing to the presence or absence of LEP (-2548) A allele (p denotes the log-rank test value) Figure 1
Breast carcinoma specific overall survival (A1) and specific disease-free survival (A2) of 308 breast carcinoma patients accord-
ing to the presence or absence of LEP (-2548) A allele (p denotes the log-rank test value).
D
i
s
e
a
s
e
-
f
r
e
e
s
u
r
v
i
v
a
l
(
%
)
P < 0.03
Time (months)
Without LEP (-2548) A
With LEP (-2548) A
A2
Time (months)
O
v
e
r
a
l
l
s
u
r
v
i
v
a
l
(
%
)
Without LEP (-2548) A
With LEP (-2548) A
P < 0.06
A1BMC Cancer 2006, 6:38 http://www.biomedcentral.com/1471-2407/6/38
Page 5 of 10
(page number not for citation purposes)
type (OR = 1.45; P = 0.04). The LEP (-2548) A allele fre-
quency was significantly higher in the patient group
compared to the control group (OR = 1.55; P = 0.001).
The allelic frequency of the LEPR 223R was 0.446 in
patients with breast carcinoma and 0.338 in control sub-
jects (OR = 1.57; P = 0.0003). The frequency of hetero-
zygous LEPR 223QR was 0.471 in the patient group and
0.405 in the control population resulting in a significantly
increased OR in the patient group bearing this genotype
(OR = 1.68; P = 0.007). The frequency of the homozygous
LEPR 223 RR was 0.211 in the patient group and only
0.135 in controls (OR = 2.26; P = 0.001). These data,
taken together, suggest that an increased risk of develop-
ing breast carcinoma is associated with the inheritance of
the  LEP (-2548) A and  LEPR 223R alleles in a dose-
dependant manner.
When we stratified the patients according to the meno-
pause status (190 pre-menopausal and 118 post-meno-
pausal) no significant changes in the LEP  and  LEPR
genotype distributions were seen in breast carcinoma sub-
groups (data not shown).
Prognostic significance of polymorphism in LEP and LEPR 
genes
Table 3 shows the distributions of LEP and LEPR poly-
morphisms according to the clinic-pathologic indices of
breast carcinoma severity.
We stratified patients according to tumor size in two sub-
groups. The first group includes tumor size less than 5 cm
(T1-T2) and the second group includes patients with
locally advanced breast cancer (T3-T4). The frequency of
the  LEP (-2548) A allele was significantly higher in
patients with larger tumor size (P = 0.05). No association
was found with the other clinic-pathologic parameters.
When we tested the relationship between the presence of
the LEP (-2548) A allele in all the 308 patients and the
survival (OVS and DFS), significant differences were
observed between the DFS Kaplan-Meier survival curves
for the different polymorphisms.
As shown in figure 1, the breast carcinoma specific DFS
was significantly shorter in the patient population carry-
ing the LEP (-2548) A allele. The estimated 3- and 6- year
breast carcinoma specific DFS rates in the group of
patients carrying the LEP (-2548) A allele were, respec-
tively, 85.29 % and 60.29 % versus the DFS rates of 95.59
% and 79.41 % for those carrying the LEP (-2548) G allele
(log rank test, P < 0.03). No statistical difference in overall
survival between both groups of patients was observed.
The breast carcinoma specific OVS was significantly
shorter in the group of patients carrying LEPR 223R allele
(Fig. 2). The estimated 3- and 6- year breast carcinoma
OVS rate in the group of patients carrying LEPR 223R
allele were, respectively, 86.76 % and 75 % versus 98.5
Breast carcinoma specific overall survival (B1) and specific disease-free survival (B2) of 308 breast carcinoma patients according  to the presence or absence of LEPR 223R allele (p denotes the log-rank test value) Figure 2
Breast carcinoma specific overall survival (B1) and specific disease-free survival (B2) of 308 breast carcinoma patients according 
to the presence or absence of LEPR 223R allele (p denotes the log-rank test value).
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and 97.06% for those carrying the 223Q allele (log rank
test,  P  < 0.01). In contrast, no association was found
between LEPR 223R and the DFS rate in this population
of patients with breast carcinoma.
Multivariate analyses were undertaken to evaluate the
importance of LEP and LEPR markers in the risk of the
recurrence and death compared with the clinicopatho-
logic parameters. Introducing the genetic and the clinico-
pathologic parameters bearing prognostic significance has
tested the Cox model. No genetic and clinicopathologic
parameters were selected for OVS and DFS.
Discussion
Leptin is a cytokine produced mainly by adipose tissue.
Leptin has recently been reported to stimulate the prolif-
eration of various cell types and is considered to be a new
growth factor. Hyperleptinemia is a common feature of
obese women who have a risk of breast cancer higher than
those with normal weight and epidemiologic studies have
suggested a positive correlation between obesity and
breast cancer risk [62].
In addition, recent studies indicate that leptin is a
mitogenic [63], as well as pro-angiogenic factor in various
cell models. New data documented that human breast
cancer cell lines and breast tumors may express leptin and
leptin receptors [40,42,47,48]. These characteristics of
leptin prompted us to evaluate whether genetic variations
of the LEP gene promoter and/or LEPR exon 6 affect sus-
ceptibility to and prognosis of breast cancer.
The present case/control study showed a substantially
increased risk of breast carcinoma associated in a dose-
dependent manner, with the inheritance of the LEP (-
2548) A allele. Individuals homozygous for LEP (-2548)
A have more than 3-fold risk to develop breast carcinoma
(OR = 3.17; P  = 0.001) compared with individuals
homozygous for LEP (-2548) G allele. The LEP (-2548)
GA heterozygotes patients have an intermediate risk for
this cancer (OR = 1.45; P = 0.04).
Comparison of genotype frequencies of the LEPR Q223R
alleles in patients with breast carcinoma and control sub-
jects indicated an increase of LEPR 223QR and RR geno-
types. Consequently, the frequency of the LEPR 223R
allele was found to be significantly higher in patients
group compared with controls.
In this study, we investigate the prognostic significance
evaluation of LEP and LEPR polymorphism by examining
the potential association of LEP -2548 and LEPR exon 6
variations and the clinical response to chemotherapy
induction. This evaluation indicated that LEP and LEPR
polymorphisms do not have a predictive value for clinical
responses to chemotherapy.
The prognostic evaluation of the LEP and LEPR genetic
markers in breast carcinoma indicated that LEP (-2548) A
allele is associated with a larger tumor size at diagnosis
and a shorter disease-free survival, and that the LEPR
223R allele is associated with shorter overall survival, and
therefore with a poor prognosis in breast carcinoma.
Table 2: The LEP (-2548) G/A and LEPR Q223R Genotype distributions in Control Subjects and in Patients with Breast Carcinoma.
Genotypes Patients (n = 308) Controls (n = 222) OR Confidence 
interval
P-value
nfnf
LEP (-2548) G/A
GG 119 (0.386) 112 (0.504) 1
GA 152 (0.494) 99 (0.446) 1.45 [0.99–2.11] 0.04
AA 37 (0.120) 11 (0.050) 3.17 [1.47–6.96] 0.001
Alleles
G-allele 390 (0.633) 323 (0.727)
A-allele 226 (0.367) 121 (0.273) 1.55 [1.18–2.04] 0.001
LEPR Q223R
QQ 98 (0.318) 102 (0.460) 1
QR 145 (0.471) 90 (0.405) 1.68 [1.12–2.50] 0.007
RR 65 (0.211) 30 (0.135) 2.26 [1.31–3.90] 0.001
Alleles
Q-allele 341 (0.554) 294 (0.662)
R-allele 275 (0.446) 150 (0.338) 158 [1.22–2.05] 0.0003
OR, odds ratio; CI, confidence interval. The χ2 test was used to determine whether significant differences (P-value) were observed when the patient 
group was compared with the control group. f, frequencies.BMC Cancer 2006, 6:38 http://www.biomedcentral.com/1471-2407/6/38
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Both functional studies and genetic analyses have high-
lighted the role of LEP and LEPR in cancer pathogenesis
and disease progression [64-67].
Previous reports demonstrated that LEP (-2548) A allele
was significantly associated with higher leptin level
[55,56]. However, the relationship between leptin level
and the LEPR Q223R polymorphism are conflicting.
Quinton et al. have indicated that LEPR 223R allele was
associated with lower circulating leptin level [68]. In con-
trast, Yiannakouris et al. have found that carriers of the
LEPR 223R allele had significantly higher leptin level than
non carriers [57].
Several studies have shown the relationship between LEP
and  LEPR  gene polymorphisms and human cancer
[66,67,69]. The LEP (-2548) A allele, which result in high
leptin secretion, was associated with increased risk of
prostate cancer [66]. Recently, a study conducted on 45
patients has reported that LEPR Q223R polymorphism is
not associated with an increased risk of breast cancer [69].
This result is in contrast with our findings.
The relationship between leptin serum level and breast
cancer is still controversial. Mantzoros et al. were
observed that leptin did not appear to increase the risk of
pre-menopausal breast cancer in situ [70]. In addition,
Petridou et al. have found no relationship between leptin
serum levels and breast cancer in post-menopausal
women [49]. A recent large study has demonstrated that
subjects with elevated serum leptin levels displayed
increased risk of developing breast cancer than those with
the normal levels [52]. Furthermore, in the same study,
the serum level of leptin was not associated with meno-
pausal status in patients with mammary disease. This
result along with our findings suggests that leptin
increased the risk of breast cancer independently from
menopausal status.
Additionnaly, in breast cancer it has been shown that a
high leptin serum level is associated with reduced OVS
[71]. Recently, it has been reported that the levels of
expression of leptin and leptin receptor correlate with dis-
tant metastasis [47]. Patients with LEPR negative and low
leptin-expressing tumors have shown an extremely good
Table 3: Genotype frequencies of LEP and LEPR polymorphisms in relation to pathological indices of breast cancer severity.
Pathological feature Number of patients (%) P-value
LEP (-2548) G/A GG GA + AA
Tumor size
T1-T2 82 (42.05) 113 (57.95) 0.05
T3-T4 21 (26.92) 57 (73.08)
Histological grade
1–2 68 (39.08) 106 (60.92) 0.3
3 28 (32.56) 58 (67.44)
Lymph node metastases
Negative 64 (42.38) 87 (57.62) 0.13
Positive 51 (34.00) 99 (66.00)
Hormone receptor status
Negative 34 (38.20) 55 (61.80) 0.36
Positive 77 (44.00) 98 (56.00)
LEPR Q223R QQ QQ + RR
Tumor size
T1-T2 56 (29.17) 136 (70.83) 0.57
T3-T4 27 (32.53) 56 (67.47)
Histological grade
1–2 58 (32.95) 118 (67.05) 0.19
3 21 (25.00) 63 (75.00)
Lymph node metastases
Negative 55 (36.67) 95 (63.33) 0.07
Positive 41 (27.15) 110 (72.85)
Hormone receptor status
Negative 40 (41.53) 49 (58.47) 0.57
Positive 85 (34.33) 90 (65.67)
OR, odds ratio; CI, confidence interval. The χ2 test was used to determine whether significant differences (P-value) were observed when the patient 
group was compared with the control group. f, frequencies.BMC Cancer 2006, 6:38 http://www.biomedcentral.com/1471-2407/6/38
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outcome, and the survival rate tended to be lower for
patients with LEPR positive or high leptin-expressing
tumors [47].
Some authors have demonstrated that leptin increase cell
proliferation which is an essential element for tumor
metastasis, through cell progression in MCF-7 human
breast cancer cells with up-regulation of PKC-α, PPARγ
and PPARα [41]. Moreover, Laud et al. have suggested that
leptin stimulated the proliferation of the mitogen-acti-
vated protein kinase (MAP kinase) pathway [40]. Leptin
may also modulate apoptosis, since it has been reported
in leukaemia cell lines that leptin acts as an inhibitor of
apoptosis [72]. In addition, leptin has been shown to pro-
mote invasiveness of renal and colonic epithelial cells via
the phosphatidylinositol 3'-kinase, rho-dependent, and
rac-dependent cascades [43]. Others have also reported
that leptin act synergistically with VEGF and fibroblast
growth factor 2 (FGF-2) to promote angiogenesis [73,74].
Moreover, leptin has been shown to increase the expres-
sion of many other genes involved in angiogenesis, for
example, MMP-2 and MMP-9 gene products [75].
Other lines of evidence derive from studies on markers of
tumoral risk that are elevated in breast cancer, that can
upregulate leptin production. Factors such as TNF-alpha
[76,77], IL-1alpha [78], IL-1 beta [79], estrogens [79], all
raise leptin levels, promoting growth and differentiation
of tumors.
The results of the current study, which show the associa-
tion between the LEP (-2548) G/A and LEPR Q223R pol-
ymorphisms and breast carcinoma susceptibility and
survival, suggest that the genetic basis of the potential
tumor promoter role attributed to LEP and its receptor
may result from certain LEP and LEPR polymorphisms.
Therefore, these polymorphisms may play a casual role in
tumor development as well as in governing poor progno-
sis of breast carcinoma.
Conclusion
In conclusion, this study suggests that genetic variation in
the tandem LEP and its receptor LEPR may be attractive
susceptibility markers for breast carcinoma. These genetic
markers represent also, prognostic variables for predicting
recurrence and death from breast carcinoma.
The role of the leptin and its receptor as genetic markers
for breast cancer can be completed with other SNPs and a
haplotype analysis.
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